comparing cardiovascular and kidney outcomes with tirzepatide vs. glp-1 agonists Free Comparison Chart: GIP/GLP-1 Receptor for Type 2 Diabetes 🔗 Link in bio #FOAMed #Type2Diabetes #GLP1 TrimRX | Cardiovascular Risks of

The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimers disease

If constipation becomes a problem despite preparation, options worth discussing with your clinician include: A gentle osmotic laxative such as polyethylene glycol (MiraLAX) used on a scheduled rather than as-needed basis during dose escalation periods

Secondary endpoints were univariately compared between the GLP-1-RA and UCWM groups

GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefitharm modelling study

Consistent with these effects, GLP-1 RAs have been associated with substantial weight loss in clinical trials, leading to FDA approval of two of these agents liraglutide and semaglutide for chronic weight management in adults with obesity or with overweight and at least one weight-related comorbidity